ArticleScientific reports2020
Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Innovative multi-epitope vaccine engineering for dual protection against Salmonella and Shigella leveraging FliC flagellin protein adjuvant properties: an immunoinformatics-based approach.Journal of translational medicine · 2026Article
- A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus infection in mice.Tropical diseases, travel medicine and vaccines · 2026Article
- Unleashing the immune arsenal: development of broad spectrum multiepitope bluetongue vaccine targeting conserved T cell epitopes of structural proteins.BMC genomics · 2026Article
- PEPNet: a two-stage point cloud framework with hierarchical embedding and antigen-antibody interaction modeling for epitope prediction.Briefings in bioinformatics · 2026Article
- BLMPred: Predicting linear B-cell epitopes using pre-trained protein language models and machine learning.Computational and structural biotechnology journal · 2026Article
- In silico design and evaluation of a multiepitope vaccine against Bordetella pertussis: structural, immunological, and biological properties.Genomics & informatics · 2025Article
- Gold Nanoparticles as a Platform for Delivery of Immunogenic Peptides to THP-1 Derived Macrophages: Insights into Nanotoxicity.Vaccines · 2025Article
- Mosaic vaccine design targeting mutational spike protein of SAR-SCoV-2: An immunoinformatics approach.BioImpacts : BI · 2025Article
- Comprehensive immunoinformatics and bioinformatics strategies for designing a multi-epitope based vaccine targeting structural proteins of Nipah virus.Frontiers in immunology · 2025Article
- In Silico Design and Characterization of a Multiepitope Vaccine Candidate AgainstJournal of immunology research · 2025Article
- A Polysaccharide-Based Oral-Vaccine Delivery System and Adjuvant for the Influenza Virus Vaccine.Vaccines · 2024Article
- Designing a smallpox B-cell and T-cell multi-epitope subunit vaccine using a comprehensive immunoinformatics approach.Microbiology spectrum · 2024Article
- Design of multi-epitope chimeric vaccine against Monkeypox virus and SARS-CoV-2: A vaccinomics perspective.Journal of cellular and molecular medicine · 2024Article
- Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine.Frontiers in immunology · 2024Article
- Designing of a new multi-epitope vaccine against Leishmania major using Leish-F1 epitopes: An In-silico study.PloS one · 2024Article
- Article
- Expression, Purification, and Evaluation of Antibody Responses and Antibody-Immunogen Complex Simulation of a Designed Multi-Epitope Vaccine against SARS-COV-2.Protein and peptide letters · 2024Article
- Multi-epitope vaccine design for hepatitis E virus based on protein ORF2 and ORF3.Frontiers in microbiology · 2024Article
- Immunodominant conserved moieties on spike protein of SARS-CoV-2 renders virulence factor for the design of epitope-based peptide vaccines.Virusdisease · 2023Article
- In silico formulation of a next-generation multiepitope vaccine for use as a prophylactic candidate against Crimean-Congo hemorrhagic fever.BMC medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is an acute pneumonic disease, with no prophylactic or specific therapeutical solution. Effective and rapid countermeasure against the spread of the disease's associated virus, SARS-CoV-2, requires to incorporate the computational approach. In this study, we employed various immunoinformatics tools to design a multi-epitope vaccine polypeptide with the highest potential for activating the human immune system against SARS-CoV-2. The initial epitope set was extracted from the whole set of viral structural proteins. Potential non-toxic and non-allergenic T-cell and B-cell binding and cytokine inducing epitopes were then identified through a priori prediction. Selected epitopes were bound to each other with appropriate linkers, followed by appending a suitable adjuvant to increase the immunogenicity of the vaccine polypeptide. Molecular modelling of the 3D structure of the vaccine construct, docking, molecular dynamics simulations and free energy calculations confirmed that the vaccine peptide had high affinity for Toll-like receptor 3 binding, and that the vaccine-receptor complex was highly stable. As our vaccine polypeptide design captures the advantages of structural epitopes and simultaneously integrates precautions to avoid relevant side effects, it is suggested to be promising for elicitation of an effective and safe immune response against SARS-CoV-2 in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.